Lauren E. Cipriano
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Lauren E. Cipriano has a total of 186 co-authors. Here are the top co-authors by number of shared publications:
- Luciano Alberto Sposato
Robarts Research Institute, Department of Clinical Neurological Sciences, and Department of Epidemiology and Biostatistics, University of Western Ontario, London, Canada; and
9 shared publications - Gustavo Saposnik
University of Toronto
7 shared publications Jeremy D. Goldhaber-Fiebert
Stanford Health Policy, Centers for Health Policy and Primary Care and Outcomes Research, Stanford University, Stanford, CA, USA
7 shared publicationsLuciano A. Sposato
Department of Clinical Neurological Sciences, Western University, London, Ontario, Canada; Department of Epidemiology and Biostatistics, Schulich School of Medicine & Dentistry, Western University, London, Ontario, Canada; Stroke, Dementia and Heart Disease Laboratory, Western University, London, Ontario, Canada; Department of Anatomy & Cell Biology, Schulich School of Medicine & Dentistry, Western University, London, Ontario, Canada
6 shared publications- Vladimir Hachinski
Department of Clinical Neurological Sciences Schulich School of Medicine and Dentistry University of Western Ontario London Ontario Canada
6 shared publications Alan M. Garber
5 shared publications
Latest Publications
- Open Access
- 15 October 2026
- Published by Elsevier in The Lancet Regional Health - Americas
- Vol. 64, 101652
HIV pre-exposure prophylaxis in US prison settings: a model-based cost-effectiveness study
- 15 October 2026
- Published by Elsevier in The Lancet Regional Health - Americas
- Vol. 64, 101652
Open AccessHIV pre-exposure prophylaxis in US prison settings: a model-based cost-effectiveness study
- Open Access
- 1 January 2025
- Published by SAGE Publications in MDM Policy & Practice
- Vol. 10 (1)
The Peer Review Process for the Making Numbers Meaningful Article Collection and Thanks to Collection Editor Marilyn Schapira
- 1 January 2025
- Published by SAGE Publications in MDM Policy & Practice
- Vol. 10 (1)
Open AccessThe Peer Review Process for the Making Numbers Meaningful Article Collection and Thanks to Collection Editor Marilyn Schapira
- 3 October 2023
- Published by Elsevier in Canadian Journal of Cardiology
- Vol. 39 (10) , S221-S222
POPULATION HEALTH VALUE OF BEING IN TARGET: RESULTS FROM THE CANADIAN MULTI-MORBIDITY MODEL FOR TYPE 2 DIABETES
- 3 October 2023
- Published by Elsevier in Canadian Journal of Cardiology
- Vol. 39 (10) , S221-S222
POPULATION HEALTH VALUE OF BEING IN TARGET: RESULTS FROM THE CANADIAN MULTI-MORBIDITY MODEL FOR TYPE 2 DIABETES
- Open Access
- 12 September 2023
- Published by SAGE Publications in Medical Decision Making
- Vol. 43 (7-8) , 914-929
Pricing Treatments Cost-Effectively when They Have Multiple Indications: Not Just a Simple Threshold Analysis
Background: Economic evaluations of treatments increasingly employ price-threshold analyses. When a treatment has multiple indications, standard price-threshold analyses can be overly simplistic. We examine how rules governing indication-specific prices and reimbursement decisions affect value-based price analyses. Methods: We analyze a 2-stage game between 2 players: the therapy’s manufacturer and the payer purchasing it for patients. First, the manufacturer selects a price(s) that may be indication specific. Then, the payer decides whether to provide reimbursement at the offered price(s). We assume known indication-specific demand. The manufacturer seeks to maximize profit. The payer seeks to maximize total population incremental net monetary benefit and will not pay more than their willingness-to-pay threshold. We consider game variants defined by constraints on the manufacturer’s ability to price and payer’s ability to provide reimbursement differentially by indication. Results: When both the manufacturer and payer can make indication-specific decisions, the problem simplifies to multiple single-indication price-threshold analyses, and the manufacturer captures all the consumer surplus. When the manufacturer is restricted to one price and the payer must make an all-or-nothing reimbursement decision, the selected price is a weighted average of indication-specific threshold prices such that reimbursement of more valuable indications subsidizes reimbursement of less valuable indications. With a single price and indication-specific coverage decisions, the manufacturer may select a high price where fewer patients receive treatment because the payer restricts reimbursement to the set of indications providing value commensurate with the high price. However, the manufacturer may select a low price, resulting in reimbursement for more indications and positive consumer surplus. Conclusions: When treatments have multiple indications, economic evaluations including price-threshold analyses should carefully consider jurisdiction-specific rules regarding pricing and reimbursement decisions. Highlights: With treatment prices rising, economic evaluations increasingly employ price-threshold analyses to identify value-based prices. Standard price-threshold analyses can be overly simplistic when treatments have multiple indications. Jurisdiction-specific rules governing indication-specific prices and reimbursement decisions affect value-based price analyses. When the manufacturer is restricted to one price for all indications and the payer must make an all-or-nothing reimbursement decision, the selected price is a weighted average of indication-specific threshold prices such that reimbursement of the more valuable indications subsidize reimbursement of the less valuable indications. With a single price and indication-specific coverage decisions, the manufacturer may select a high price with fewer patients treated than in the first-best solution. There are also cases in which the manufacturer selects a lower price, resulting in reimbursement for more indications and positive consumer surplus.
- 12 September 2023
- Published by SAGE Publications in Medical Decision Making
- Vol. 43 (7-8) , 914-929
Open AccessPricing Treatments Cost-Effectively when They Have Multiple Indications: Not Just a Simple Threshold Analysis
Background: Economic evaluations of treatments increasingly employ price-threshold analyses. When a treatment has multiple indications, standard price-threshold analyses can be overly simplistic. We examine how rules governing indication-specific prices and reimbursement decisions affect value-based price analyses. Methods: We analyze a 2-stage game between 2 players: the therapy’s manufacturer and the payer purchasing it for patients. First, the manufacturer selects a price(s) that may be indication specific. Then, the payer decides whether to provide reimbursement at the offered price(s). We assume known indication-specific demand. The manufacturer seeks to maximize profit. The payer seeks to maximize total population incremental net monetary benefit and will not pay more than their willingness-to-pay threshold. We consider game variants defined by constraints on the manufacturer’s ability to price and payer’s ability to provide reimbursement differentially by indication. Results: When both the manufacturer and payer can make indication-specific decisions, the problem simplifies to multiple single-indication price-threshold analyses, and the manufacturer captures all the consumer surplus. When the manufacturer is restricted to one price and the payer must make an all-or-nothing reimbursement decision, the selected price is a weighted average of indication-specific threshold prices such that reimbursement of more valuable indications subsidizes reimbursement of less valuable indications. With a single price and indication-specific coverage decisions, the manufacturer may select a high price where fewer patients receive treatment because the payer restricts reimbursement to the set of indications providing value commensurate with the high price. However, the manufacturer may select a low price, resulting in reimbursement for more indications and positive consumer surplus. Conclusions: When treatments have multiple indications, economic evaluations including price-threshold analyses should carefully consider jurisdiction-specific rules regarding pricing and reimbursement decisions. Highlights: With treatment prices rising, economic evaluations increasingly employ price-threshold analyses to identify value-based prices. Standard price-threshold analyses can be overly simplistic when treatments have multiple indications. Jurisdiction-specific rules governing indication-specific prices and reimbursement decisions affect value-based price analyses. When the manufacturer is restricted to one price for all indications and the payer must make an all-or-nothing reimbursement decision, the selected price is a weighted average of indication-specific threshold prices such that reimbursement of the more valuable indications subsidize reimbursement of the less valuable indications. With a single price and indication-specific coverage decisions, the manufacturer may select a high price with fewer patients treated than in the first-best solution. There are also cases in which the manufacturer selects a lower price, resulting in reimbursement for more indications and positive consumer surplus.
- Open Access
Pricing Treatments Cost-Effectively When They Have Multiple Indications: Not Just a Simple Threshold Analysis
Background: Economic evaluations of treatments increasingly employ price-threshold analyses. When a treatment has multiple indications, standard price-threshold analyses can be overly simplistic. We examine how rules governing indication-specific prices and reimbursement decisions impact value-based price analyses. Methods: We analyze a two-stage game between two players: the therapy’s manufacturer and payer purchasing it for patients. First, the manufacturer selects a price(s) that may be indication-specific. Then, the payer decides whether to provide reimbursement at the offered price(s). We assume known indication-specific demand. The manufacturer seeks to maximize profit, requiring non-negative profit. The payer seeks to maximize total population incremental net monetary benefit and will not pay more than their willingness-to-pay threshold. We consider game variants defined by constraints on the manufacturer’s ability to price and payer’s ability to provide reimbursement differentially by indication. Results: When the manufacturer and payer can both make indication-specific decisions, the problem simplifies to single-indication price-threshold analyses, and the manufacturer captures all the consumer surplus. When the manufacturer is restricted to one price and the payer must make an all-or-nothing reimbursement decision, the selected price is a weighted average of indication-specific threshold prices such that reimbursement of the more valuable indications subsidize reimbursement of the less valuable indications. With a single price and indication-specific coverage decisions, the manufacturer may select a high price and fewer patients receive treatment than in the first-best solution. However, there are also cases when the manufacturer selects a low price resulting in reimbursement for all indications and positive consumer surplus. Conclusions: When multiple indications exist for a given treatment, economic evaluations including price-threshold analyses should carefully consider jurisdiction-specific rules regarding pricing and reimbursement decisions.
Open AccessPricing Treatments Cost-Effectively When They Have Multiple Indications: Not Just a Simple Threshold Analysis
Background: Economic evaluations of treatments increasingly employ price-threshold analyses. When a treatment has multiple indications, standard price-threshold analyses can be overly simplistic. We examine how rules governing indication-specific prices and reimbursement decisions impact value-based price analyses. Methods: We analyze a two-stage game between two players: the therapy’s manufacturer and payer purchasing it for patients. First, the manufacturer selects a price(s) that may be indication-specific. Then, the payer decides whether to provide reimbursement at the offered price(s). We assume known indication-specific demand. The manufacturer seeks to maximize profit, requiring non-negative profit. The payer seeks to maximize total population incremental net monetary benefit and will not pay more than their willingness-to-pay threshold. We consider game variants defined by constraints on the manufacturer’s ability to price and payer’s ability to provide reimbursement differentially by indication. Results: When the manufacturer and payer can both make indication-specific decisions, the problem simplifies to single-indication price-threshold analyses, and the manufacturer captures all the consumer surplus. When the manufacturer is restricted to one price and the payer must make an all-or-nothing reimbursement decision, the selected price is a weighted average of indication-specific threshold prices such that reimbursement of the more valuable indications subsidize reimbursement of the less valuable indications. With a single price and indication-specific coverage decisions, the manufacturer may select a high price and fewer patients receive treatment than in the first-best solution. However, there are also cases when the manufacturer selects a low price resulting in reimbursement for all indications and positive consumer surplus. Conclusions: When multiple indications exist for a given treatment, economic evaluations including price-threshold analyses should carefully consider jurisdiction-specific rules regarding pricing and reimbursement decisions.
- Open Access
- 28 December 2022
- Published by SAGE Publications in Medical Decision Making
- Vol. 43 (2) , 147-149
Evaluating the Impact and Potential Impact of Machine Learning on Medical Decision Making
- 28 December 2022
- Published by SAGE Publications in Medical Decision Making
- Vol. 43 (2) , 147-149
Open AccessEvaluating the Impact and Potential Impact of Machine Learning on Medical Decision Making
- 12 April 2022
- Published by SAGE Publications in Medical Decision Making
- Vol. 42 (4) , 419-420
Author Response to “Optimal Sample Size Calculation for Clinical Research under a Budget Constraint”
- 12 April 2022
- Published by SAGE Publications in Medical Decision Making
- Vol. 42 (4) , 419-420
Author Response to “Optimal Sample Size Calculation for Clinical Research under a Budget Constraint”
- 1 April 2022
- Published by Wolters Kluwer Health in Stroke
- Vol. 53 (4) , 1170-1177
Intravenous Thrombolysis After First-Ever Ischemic Stroke and Reduced Incident Dementia Rate
Background: The use of intravenous thrombolysis is associated with improved clinical outcomes. Whether thrombolysis is associated with reduced incidence of poststroke dementia remains uncertain. We sought to estimate if the use of thrombolysis following first-ever ischemic stroke was associated with a reduced rate of incident dementia using a pragmatic observational design. Methods: We included first-ever ischemic stroke patients from the Ontario Stroke Registry who had not previously been diagnosed with dementia. The primary outcome was incident dementia ascertained by a validated diagnostic algorithm. We employed inverse probability of treatment-weighted Cox proportional hazard models to estimate the cause-specific hazard ratio for the association of thrombolysis and incident dementia at 1 and 5 years following stroke. Results: From July 2003 to March 2013, 7072 patients with ischemic stroke were included, 3276 (46.3%) were female and mean age was 71.0 (SD, 12.8) years. Overall, 38.2% of the cohort (n=2705) received thrombolysis, 77.2% (n=2087) of which was administered within 3 hours of stroke onset. In the first year following stroke, thrombolysis administration was associated with a 24% relative reduction in the rate of developing dementia (cause-specific hazard ratio, 0.76 [95% CI, 0.58–0.97]). This association remained significant at 5 years (cause-specific hazard ratio, 0.79 [95% CI, 0.66–0.91]) and at the end of follow-up (median 6.3 years; cause-specific hazard ratio, 0.79 [95% CI, 0.68–0.89]). Conclusions: Thrombolysis administration following first-ever ischemic stroke was independently associated with a reduced rate of dementia. Incident dementia should be considered as a relevant outcome when evaluating risk/benefit of thrombolysis in ischemic stroke patients.
- 1 April 2022
- Published by Wolters Kluwer Health in Stroke
- Vol. 53 (4) , 1170-1177
Intravenous Thrombolysis After First-Ever Ischemic Stroke and Reduced Incident Dementia Rate
Background: The use of intravenous thrombolysis is associated with improved clinical outcomes. Whether thrombolysis is associated with reduced incidence of poststroke dementia remains uncertain. We sought to estimate if the use of thrombolysis following first-ever ischemic stroke was associated with a reduced rate of incident dementia using a pragmatic observational design. Methods: We included first-ever ischemic stroke patients from the Ontario Stroke Registry who had not previously been diagnosed with dementia. The primary outcome was incident dementia ascertained by a validated diagnostic algorithm. We employed inverse probability of treatment-weighted Cox proportional hazard models to estimate the cause-specific hazard ratio for the association of thrombolysis and incident dementia at 1 and 5 years following stroke. Results: From July 2003 to March 2013, 7072 patients with ischemic stroke were included, 3276 (46.3%) were female and mean age was 71.0 (SD, 12.8) years. Overall, 38.2% of the cohort (n=2705) received thrombolysis, 77.2% (n=2087) of which was administered within 3 hours of stroke onset. In the first year following stroke, thrombolysis administration was associated with a 24% relative reduction in the rate of developing dementia (cause-specific hazard ratio, 0.76 [95% CI, 0.58–0.97]). This association remained significant at 5 years (cause-specific hazard ratio, 0.79 [95% CI, 0.66–0.91]) and at the end of follow-up (median 6.3 years; cause-specific hazard ratio, 0.79 [95% CI, 0.68–0.89]). Conclusions: Thrombolysis administration following first-ever ischemic stroke was independently associated with a reduced rate of dementia. Incident dementia should be considered as a relevant outcome when evaluating risk/benefit of thrombolysis in ischemic stroke patients.
- Open Access
MITIGATING THE 4 th WAVE OF THE COVID-19 PANDEMIC IN ONTARIO
Background: The goal of this study was to project the number of COVID-19 cases and demand for acute hospital resources for Fall of 2021 in a representative mid-sized community in southwestern Ontario. We sought to evaluate whether current levels of vaccine coverage and contact reduction could mitigate a potential 4 th wave fueled by the Delta variant, or whether the reinstitution of more intense public health measures will be required. Methods: We developed an age-stratified dynamic transmission model of COVID-19 in a mid-sized city (population 500,000) currently experiencing a relatively low, but increasing, infection rate in Step 3 of Ontario’s Wave 3 recovery. We parameterized the model using the medical literature, grey literature, and government reports. We estimated the current level of contact reduction by model calibration to cases and hospitalizations. We projected the number of infections, number of hospitalizations, and the time to re-instate high intensity public health measures over the fall of 2021 under different levels of vaccine coverage and contact reduction. Results: Maintaining contact reductions at the current level, estimated to be a 17% reduction compared to pre-pandemic contact levels, results in COVID-related admissions exceeding 20% of pre-pandemic critical care capacity by late October, leading to cancellation of elective surgeries and other non-COVID health services. At high levels of vaccination and relatively high levels of mask wearing, a moderate additional effort to reduce contacts (30% reduction compared to pre-pandemic contact levels), is necessary to avoid re-instating intensive public health measures. Compared to prior waves, the age distribution of both cases and hospitalizations shifts younger and the estimated number of pediatric critical care hospitalizations may substantially exceed 20% of capacity. Discussion: High rates of vaccination coverage in people over the age of 12 and mask wearing in public settings will not be sufficient to prevent an overwhelming resurgence of COVID-19 in the Fall of 2021. Our analysis indicates that immediate moderate public health measures can prevent the necessity for more intense and disruptive measures later.
Open AccessMITIGATING THE 4 th WAVE OF THE COVID-19 PANDEMIC IN ONTARIO
Background: The goal of this study was to project the number of COVID-19 cases and demand for acute hospital resources for Fall of 2021 in a representative mid-sized community in southwestern Ontario. We sought to evaluate whether current levels of vaccine coverage and contact reduction could mitigate a potential 4 th wave fueled by the Delta variant, or whether the reinstitution of more intense public health measures will be required. Methods: We developed an age-stratified dynamic transmission model of COVID-19 in a mid-sized city (population 500,000) currently experiencing a relatively low, but increasing, infection rate in Step 3 of Ontario’s Wave 3 recovery. We parameterized the model using the medical literature, grey literature, and government reports. We estimated the current level of contact reduction by model calibration to cases and hospitalizations. We projected the number of infections, number of hospitalizations, and the time to re-instate high intensity public health measures over the fall of 2021 under different levels of vaccine coverage and contact reduction. Results: Maintaining contact reductions at the current level, estimated to be a 17% reduction compared to pre-pandemic contact levels, results in COVID-related admissions exceeding 20% of pre-pandemic critical care capacity by late October, leading to cancellation of elective surgeries and other non-COVID health services. At high levels of vaccination and relatively high levels of mask wearing, a moderate additional effort to reduce contacts (30% reduction compared to pre-pandemic contact levels), is necessary to avoid re-instating intensive public health measures. Compared to prior waves, the age distribution of both cases and hospitalizations shifts younger and the estimated number of pediatric critical care hospitalizations may substantially exceed 20% of capacity. Discussion: High rates of vaccination coverage in people over the age of 12 and mask wearing in public settings will not be sufficient to prevent an overwhelming resurgence of COVID-19 in the Fall of 2021. Our analysis indicates that immediate moderate public health measures can prevent the necessity for more intense and disruptive measures later.
- Open Access
- 12 August 2021
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 16 (8) , e0255782
Impact of university re-opening on total community COVID-19 burden
Background: University students have higher average number of contacts than the general population. Students returning to university campuses may exacerbate COVID-19 dynamics in the surrounding community. Methods: We developed a dynamic transmission model of COVID-19 in a mid-sized city currently experiencing a low infection rate. We evaluated the impact of 20,000 university students arriving on September 1 in terms of cumulative COVID-19 infections, time to peak infections, and the timing and peak level of critical care occupancy. We also considered how these impacts might be mitigated through screening interventions targeted to students. Results: If arriving students reduce their contacts by 40% compared to pre-COVID levels, the total number of infections in the community increases by 115% (from 3,515 to 7,551), with 70% of the incremental infections occurring in the general population, and an incremental 19 COVID-19 deaths. Screening students every 5 days reduces the number of infections attributable to the student population by 42% and the total COVID-19 deaths by 8. One-time mass screening of students prevents fewer infections than 5-day screening, but is more efficient, requiring 196 tests needed to avert one infection instead of 237. Interpretation: University students are highly inter-connected with the surrounding off-campus community. Screening targeted at this population provides significant public health benefits to the community through averted infections, critical care admissions, and COVID-19 deaths.
- 12 August 2021
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 16 (8) , e0255782
Open AccessImpact of university re-opening on total community COVID-19 burden
Background: University students have higher average number of contacts than the general population. Students returning to university campuses may exacerbate COVID-19 dynamics in the surrounding community. Methods: We developed a dynamic transmission model of COVID-19 in a mid-sized city currently experiencing a low infection rate. We evaluated the impact of 20,000 university students arriving on September 1 in terms of cumulative COVID-19 infections, time to peak infections, and the timing and peak level of critical care occupancy. We also considered how these impacts might be mitigated through screening interventions targeted to students. Results: If arriving students reduce their contacts by 40% compared to pre-COVID levels, the total number of infections in the community increases by 115% (from 3,515 to 7,551), with 70% of the incremental infections occurring in the general population, and an incremental 19 COVID-19 deaths. Screening students every 5 days reduces the number of infections attributable to the student population by 42% and the total COVID-19 deaths by 8. One-time mass screening of students prevents fewer infections than 5-day screening, but is more efficient, requiring 196 tests needed to avert one infection instead of 237. Interpretation: University students are highly inter-connected with the surrounding off-campus community. Screening targeted at this population provides significant public health benefits to the community through averted infections, critical care admissions, and COVID-19 deaths.